ClinicalTrials.gg
CompletedNCT06095557Updated Oct 21, 2025

MCG Discovery Study in Emergency Departments

An interventional study of Sponsor MCG device in ACS - Acute Coronary Syndrome and NSTEMI - Non-ST Segment Elevation MI, sponsored by SB Technology, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by SB Technology, Inc. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Enrollment
102nd of 186
124 · median 150
Started
2023
with 5 others
No phase
73 of 265
5 open now
Registered
251st of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 102nd largest by enrollment of the 186 interventional ones that give a count, is one of 6 that started in 2023, is one of 73 with no phase, and was the 251st registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting. The main question it aims to answer is whether interpretable data can be reliably collected as part of an ED workflow.

03

Conditions studied

  • ACS - Acute Coronary Syndrome
  • NSTEMI - Non-ST Segment Elevation MI

Keywords

  • magnetocardiography
  • MCG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presents to ED with symptoms of Acute Coronary Syndrome (ACS)
  • Can provide written consent

Exclusion criteria

Exclusion Criteria:

  • Presents to ED with ST-Elevation Myocardial Infarction (STEMI)
  • Presents to ED with Atrial Fibrillation
  • Clear non-ischemic cause for symptoms (i.e. trauma)
  • Active thoracic metal implants
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Sponsor MCG device

    All participants will receive a scan from the Sponsor MCG device

    Device: Sponsor MCG device

Interventions

  • DeviceSponsor MCG device

    unshielded device measuring cardiac magnetic fields

06

What researchers measure

Primary outcomes

  1. % analyzable Sandbox MCG data

    % Sandbox MCG data collected and suitable for analysis

    Time frame: during the procedure (MCG scan)

Secondary outcomes

  1. Sandbox MCG safety

    Device-related adverse events

    Time frame: 30 days

  2. Characterization of scan results that may differentiate between high risk and low risk ACS patients

    Signal Noise Ratio of ECG features

    Time frame: during the procedure (MCG scan)

  3. Characterization of scan results that may differentiate between high risk and low risk ACS patients

    t-wave field maximum angle

    Time frame: during the procedure (MCG scan)

  4. Characterization of scan results that may differentiate between high risk and low risk ACS patients

    heartbeats needed to obtain signal

    Time frame: during the procedure (MCG scan)

07

Study locations

1 site
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jun 2025, 19 months.

Of 228 interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 46. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Oct 23, 2023
StartActual
Oct 30, 2023
Primary completionActual
Jun 9, 2025
CompletionActual
Jul 8, 2025
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06095557
Lead sponsor
SB Technology, Inc.
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Oct 30, 2023
Primary completion
Jun 9, 2025
Completion
Jul 8, 2025
Last update
Oct 21, 2025

Study contacts

Kit Yee Au-Yeung, PhD
study director · SB Technology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion